DRTS – alpha tau medical ltd. - ordinary shares (US:NASDAQ)

News

Alpha Tau Announces Presentation of Two Alpha DaRT Pancreatic Cancer Abstracts at Upcoming 2026 ASCO GI Symposium
Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Locally Recurrent Prostate Cancer
Alpha Tau to Participate in December Investor Conferences [Yahoo! Finance]
Alpha Tau to Participate in December Investor Conferences
Alpha Tau Medical (NASDAQ:DRTS) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $9.00 price target on the stock.
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com